Connecting - News - Information
Wednesday, 3 May 2017
INVIVOSCRIBE® RECEIVES FDA APPROVAL FOR THE LEUKOSTRAT® CDX FLT3 MUTATION ASSAY COMPANION DIAGNOSTIC TEST FOR THE SELECTION OF PATIENTS FOR RYDAPT® AND IS THE FIRST COMPANION DIAGNOSTIC FOR AML
INVIVOSCRIBE® RECEIVES FDA APPROVAL FOR THE LEUKOSTRAT® CDX FLT3 MUTATION ASSAY COMPANION DIAGNOSTIC TEST FOR THE SELECTION OF PATIENTS FOR RYDAPT® AND IS THE FIRST COMPANION DIAGNOSTIC FOR AML
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment